Checking heart function early after CAR-T cell treatment
Studies heart function by ultrasound in adults after CAR-T cell treatment for blood cancers.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Early Assessment of Cardiac Function After Treatment With CAR-T Cells
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 7 Nov 2024
- Expected to end
- Mar 2027
- Type of study
- Observational
- Record updated
- 2 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who got CAR-T cell treatment 3 to 5 days before a heart ultrasound, to check early effects on the heart.
- Age
- 18 years or older
- Sex
- All sexes can join
- Earlier treatment
- CAR-T cells given 3 to 5 days before the heart ultrasound; a heart ultrasound and EKG done before the treatment
Main reasons for not taking part
- People who refuse to take part or withdraw their consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- CAR-T cells infusion received within 3 to 5 days before the echocardiography
- Pre-therapeutic cardiac assessment (in accordance with the recommendations and standard care protocol in force in the hematology department of Saint-Antoine Hospital): Echocardiography and EKG before conditioning and infusion of CAR -T cells,
- Not opposed to participating in research
- Patient affiliated to a social security system or beneficiary of the "state medical insurance help" (namely aide médicale d'état)
Who cannot take part
- Opposition or consent withdrawal
Where in France
- Critical care medicine departmentParis, FranceContact: Jérémie JOFFRE, MD, PhDTaking people
About the trial
What the trial wants to find out
CAR-T cells (Chimeric Antigen Receptor) are a new immunotherapy, based on the genetic modification of autologous T lymphocytes. CAR-T cell therapy is not devoid of complications.
Read full original descriptionShow less
Among the most frequent complications are the risk of infection, cytokine release syndrome (CRS) and neurotoxicity. Nevertheless, some authors have reported serious acute cardiac events in a limited number of patients, often contemporaneous with CRS or sepsis, questioning the imputability of CAR-T cells in this heart disease.
This study aims to estimate the incidence of a possible early cardiotoxicity associated with CAR-T cells.
The main endpoint will be the change in cardiac function (LVEF: left ventricular ejection fraction) assessed by ultrasound between the pre CAR-T assessment and the early post CAR-T ultrasound (D3-D5).
The group in the trial
- Cardio CAR-T
Transthoracic bedside echocardiography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Early Assessment of Cardiac Function After Treatment With CAR-T Cells
- Plain-language title
- Checking heart function early after CAR-T cell treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 September 2025